Cancer Cell:多梳抑制复合体1能够驱使双阴性前列腺癌的转移

2019-09-07 AlexYang MedSci原创

最近,有研究人员阐释了多梳抑制复合体1通过协调干细胞和免疫抑制,能够驱使双阴性前列腺癌转移的机制。目前,转移位点的免疫逃避机制仍旧不清楚。他们展示了多梳抑制复合体1(PRC1)能够促使双阴性前列腺癌(DNPC)中骨骼和内脏器官的定植。体内遗传筛选鉴定了CCL2是PRC1诱导的首要促转移基因。CCL2能够调控自我更新和诱导类M2肿瘤相关巨噬细胞和调节性T细胞的招募,从而通过免疫抑制和血管生长来协调转

最近,有研究人员阐释了多梳抑制复合体1通过协调干细胞免疫抑制,能够驱使双阴性前列腺癌转移的机制。

目前,转移位点的免疫逃避机制仍旧不清楚。他们展示了多梳抑制复合体1(PRC1)能够促使双阴性前列腺癌(DNPC)中骨骼和内脏器官的定植。体内遗传筛选鉴定了CCL2是PRC1诱导的首要促转移基因。CCL2能够调控自我更新和诱导类M2肿瘤相关巨噬细胞和调节性T细胞的招募,从而通过免疫抑制和血管生长来协调转移起始。在遗传工程小鼠DNPC移植模型中,PRC1的一种催化抑制剂能够与免疫检查点疗法组合来逆转上述过程,并抑制转移。

他们的结果阐释了PRC1能够协调干细胞和免疫逃避以及心血管生成,同时也指出了PRC1在DNPC中可能的临床应用。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1961704, encodeId=bfae1961e0459, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Jul 18 02:21:00 CST 2020, time=2020-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871418, encodeId=d6ca18e1418ab, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun May 17 11:21:00 CST 2020, time=2020-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937742, encodeId=f62a193e742ac, content=<a href='/topic/show?id=ca28426010b' target=_blank style='color:#2F92EE;'>#复合体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42601, encryptionId=ca28426010b, topicName=复合体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=bioon1, createdTime=Tue Oct 29 13:21:00 CST 2019, time=2019-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780779, encodeId=37271e80779e3, content=<a href='/topic/show?id=517a4016ac' target=_blank style='color:#2F92EE;'>#cancer cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4016, encryptionId=517a4016ac, topicName=cancer cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Wed Jul 01 02:21:00 CST 2020, time=2020-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040539, encodeId=26b5104053969, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sat Sep 07 16:21:00 CST 2019, time=2019-09-07, status=1, ipAttribution=)]
    2020-07-18 维他命
  2. [GetPortalCommentsPageByObjectIdResponse(id=1961704, encodeId=bfae1961e0459, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Jul 18 02:21:00 CST 2020, time=2020-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871418, encodeId=d6ca18e1418ab, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun May 17 11:21:00 CST 2020, time=2020-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937742, encodeId=f62a193e742ac, content=<a href='/topic/show?id=ca28426010b' target=_blank style='color:#2F92EE;'>#复合体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42601, encryptionId=ca28426010b, topicName=复合体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=bioon1, createdTime=Tue Oct 29 13:21:00 CST 2019, time=2019-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780779, encodeId=37271e80779e3, content=<a href='/topic/show?id=517a4016ac' target=_blank style='color:#2F92EE;'>#cancer cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4016, encryptionId=517a4016ac, topicName=cancer cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Wed Jul 01 02:21:00 CST 2020, time=2020-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040539, encodeId=26b5104053969, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sat Sep 07 16:21:00 CST 2019, time=2019-09-07, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1961704, encodeId=bfae1961e0459, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Jul 18 02:21:00 CST 2020, time=2020-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871418, encodeId=d6ca18e1418ab, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun May 17 11:21:00 CST 2020, time=2020-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937742, encodeId=f62a193e742ac, content=<a href='/topic/show?id=ca28426010b' target=_blank style='color:#2F92EE;'>#复合体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42601, encryptionId=ca28426010b, topicName=复合体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=bioon1, createdTime=Tue Oct 29 13:21:00 CST 2019, time=2019-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780779, encodeId=37271e80779e3, content=<a href='/topic/show?id=517a4016ac' target=_blank style='color:#2F92EE;'>#cancer cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4016, encryptionId=517a4016ac, topicName=cancer cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Wed Jul 01 02:21:00 CST 2020, time=2020-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040539, encodeId=26b5104053969, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sat Sep 07 16:21:00 CST 2019, time=2019-09-07, status=1, ipAttribution=)]
    2019-10-29 bioon1
  4. [GetPortalCommentsPageByObjectIdResponse(id=1961704, encodeId=bfae1961e0459, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Jul 18 02:21:00 CST 2020, time=2020-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871418, encodeId=d6ca18e1418ab, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun May 17 11:21:00 CST 2020, time=2020-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937742, encodeId=f62a193e742ac, content=<a href='/topic/show?id=ca28426010b' target=_blank style='color:#2F92EE;'>#复合体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42601, encryptionId=ca28426010b, topicName=复合体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=bioon1, createdTime=Tue Oct 29 13:21:00 CST 2019, time=2019-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780779, encodeId=37271e80779e3, content=<a href='/topic/show?id=517a4016ac' target=_blank style='color:#2F92EE;'>#cancer cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4016, encryptionId=517a4016ac, topicName=cancer cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Wed Jul 01 02:21:00 CST 2020, time=2020-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040539, encodeId=26b5104053969, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sat Sep 07 16:21:00 CST 2019, time=2019-09-07, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1961704, encodeId=bfae1961e0459, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Jul 18 02:21:00 CST 2020, time=2020-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871418, encodeId=d6ca18e1418ab, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun May 17 11:21:00 CST 2020, time=2020-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937742, encodeId=f62a193e742ac, content=<a href='/topic/show?id=ca28426010b' target=_blank style='color:#2F92EE;'>#复合体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42601, encryptionId=ca28426010b, topicName=复合体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=bioon1, createdTime=Tue Oct 29 13:21:00 CST 2019, time=2019-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780779, encodeId=37271e80779e3, content=<a href='/topic/show?id=517a4016ac' target=_blank style='color:#2F92EE;'>#cancer cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4016, encryptionId=517a4016ac, topicName=cancer cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Wed Jul 01 02:21:00 CST 2020, time=2020-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040539, encodeId=26b5104053969, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sat Sep 07 16:21:00 CST 2019, time=2019-09-07, status=1, ipAttribution=)]
    2019-09-07 misszhang

    前列腺癌相关研究,学习了,谢谢梅斯

    0

相关资讯

Eur Urol:阿比特龙在高和低风险转移激素敏感性前列腺癌中的研究

在LATITUDE试验发现中,醋酸阿比特龙被用于且只用于高风险转移性无激素治疗前列腺癌(mHNPC)的治疗。然而,风险相关的影响在STAMPEDE试验中却并没有结果。因此,那些LATITUDE低风险M1疾病的男性患者是否从雄激素剥夺治疗(ADT)联合醋酸阿比特龙和泼尼松龙(AAP)治疗中受益仍旧不确定。最近,有研究人员评估了STAMPEDE试验中接受ADT+AAP治疗的LATITUDE高风险和低风

Radiology:VERDICT MRI诊断前列腺癌的价值

背景:扩散MRI能够评价前列腺癌成分信号,间接评价能够反映前列腺癌生物学习性,从而具有生物特异性。评价血管、细胞外和反映肿瘤内细胞计数的扩散受限程度模型对3种不同信号成分分析的价值,并与细胞内水分子、细胞外血管外空间水分子和微结构内水分子相关联。本研究旨在评价由VERDICT前列腺MRI所得细胞内体积分数(FIC)图的可重复性、图像质量和诊断效能,比较FIC图与表观扩散系数(ADC)图对Gleas

Sci Rep:雄激素阻断治疗期间优先局部治疗和前列腺特异性抗原动力学对去势难治性前列腺癌生存的影响研究

在去势难治性前列腺癌(CRPC)中,前列腺特异性抗原(PSA)动力学能够预测生存;然而,优先治疗对上述预测关系的影响仍旧不清楚。最近,有研究人员根据到PSA最低点时间和CRPC进展时间对CRPC患者进行了分层,从而来调查它们对前列腺癌特异性生存(PCSS)的预后意义以及是否在不考虑优先局部治疗的情况下,PSA动力学能够作为预测因子。他们的多中心回顾性研究包括了295名诊断为CRPC的患者,时间为2

PNAS:癌症治疗里程碑背后的故事:父亲是我搞研究的力量源泉

无需化疗!不用手术!拒绝放射治疗!美国莱斯大学开发的一种新型癌症疗法已经跨越了临床试验中的里程碑。

Sci Rep:新诊断转移前列腺癌患者中血清生物标记早期变化的预后意义

最近,有研究人员评估了血清生物标记水平的早期变化对患有转移激素敏感性前列腺癌(mHSPC)患者生存的影响,且这些患者起初是通过雄激素阻断疗法(ADTR)来治疗的。研究人员回顾性的调查了330mHSPC患者在基线和2-4个月时的血清标记水平,并建立了最优Cox回顾模型。研究发现,癌症特异生存(CSS)均值和总生存(OS)均值分别为7.08年和6.42年(平均跟踪调查时间为2.53年)。在最终的最优C

CA Cancer J Clin:2019年年龄不小于85岁成年人癌症统计研究

在美国,年龄不小于85岁的老年人口在快速的增长,而他们的癌症状况仍旧所知甚少。最近,有研究人员综合不同的数据库全面的提供了年龄不小于85岁老年人的癌症发生情况。研究发现,在2019年,美国将会大约诊断140690个癌症案例,且将有103250例癌症死亡。在这些个体中最常见的癌症为肺、乳腺、前列腺和结肠直肠癌,这与普通人群相同。总的癌症发生率在男性和女性中的峰值在1990年,之后发生率加速减少。这些